Inspiremd, INC Form 4 insider transactions

InspireMD Director Paul Stuka is set to purchase 20,661 shares of common stock at $2.42 per share through a private placement scheduled for July 30, 2025.

InspireMD, Inc. Director Michael Berman filed a Form 4 to disclose the beneficial ownership of common stock and Series I Warrants held by the Michael Berman Revocable Trust, clarifying no direct transaction was effected by the reporting person.

InspireMD Director Thomas J. Kester acquired 30,624 shares of common stock by exercising Series I Warrants at $1.3827 per share.

An entity controlled by InspireMD Director Paul Stuka acquired 87,500 common shares and warrants, increasing his reported beneficial ownership in the company.

InspireMD Director Gary S. Roubin acquired 30,624 shares of common stock at $1.3827 per share through the exercise of Series I Warrants, increasing his direct beneficial ownership to 567,103 shares.

Andrea Tommasoli, Chief Operating Officer of InspireMD, Inc., reports the acquisition and disposal of common stock and options.

Director Thomas J. Kester reports acquisition of restricted stock and options in InspireMD, Inc.

Director Scott R. Ward reports acquisition of common stock and options in InspireMD, Inc.

Director Gary S. Roubin reports acquisition and disposal of InspireMD, Inc. stock and options.

CEO Marvin Slosman reports acquisition and disposal of InspireMD stock and stock options.

Director Kathryn Arnold reports acquisition and disposal of InspireMD common stock and options.

EVP Patrick Verta reports acquisition and disposal of InspireMD stock and options, including grants that vest over three years.

Director Paul Stuka reports acquisition of InspireMD shares and options, along with an indirect disposal of shares held by Osiris Investment Partners.

Shane Gleason, Chief Commercial Officer of InspireMD, reports acquisition and disposal of common stock and options.

Director Michael Berman reports acquisition and disposal of InspireMD, Inc. shares, including restricted stock and options.

Craig Shore, CFO and CAO of InspireMD, acquired shares of common stock and options to purchase common stock on January 7, 2025.

Director Michael Berman reports acquisition of InspireMD shares and warrants, along with indirect holdings through a revocable trust.

Director Thomas J. Kester reports acquiring and disposing of InspireMD shares and warrants on May 28, 2024.

Director Paul Stuka acquired 87,500 shares of InspireMD, Inc. at $1.3827 per share on June 5, 2024, while also reporting beneficial ownership of securities held by Osiris Investment Partners, L.P.

Director Gary S. Roubin acquired shares and warrants of InspireMD, Inc. on May 28, 2024.